Navigating USPTO Challenges: Overcoming Hurdles in Antibody Patent Claims

Many patent applicants are finding it increasingly challenging to obtain antibody claims due to the United States Patent & Trademark Office’s rejections based on written description and enablement requirements as outlined in 35 U.S.C. §112(a). The USPTO often deems these claims too broad, suggesting they encompass more antibodies than disclosed in the specification, or that substantial experimentation would be necessary to ascertain if an antibody falls within the claims. This trend demands more extensive laboratory work, raising costs to achieve a §112(a)-compliant specification. The legal framework around these requirements is well-established, as demonstrated in cases such as Vas-Cath, Inc. v. Mahurkar and Ariad Pharm., Inc. v. Eli Lilly & Co., among others. These cases underscore that the specification must clearly demonstrate that the inventor was in possession of the claimed invention as of the filing date, and should enable a person skilled in the art to make and use the invention without undue experimentation. For more details on addressing these USPTO rejections, consider exploring the original article on Law.com.